Welcome to LookChem.com Sign In|Join Free

CAS

  • or

6552-63-2

Post Buying Request

6552-63-2 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

6552-63-2 Usage

General Description

1-(4-chlorophenyl)-3-(4-methoxyphenyl)prop-2-en-1-one is a chemical compound with the molecular formula C16H13ClO2. It is a yellow crystalline solid that is used in the synthesis of pharmaceuticals and other organic compounds. 1-(4-CHLOROPHENYL)-3-(4-METHOXYPHENYL)PROP-2-EN-1-ONE is a chalcone derivative, which means it has a central 1,3-diphenylpropenone scaffold with a chlorine atom on one phenyl ring and a methoxy group on the other. Chalcones have been studied for their potential anti-cancer, anti-inflammatory, and antimicrobial properties, and 1-(4-chlorophenyl)-3-(4-methoxyphenyl)prop-2-en-1-one may have similar biological activities. Its chemical structure and properties make it a valuable building block in organic synthesis and medicinal chemistry.

Check Digit Verification of cas no

The CAS Registry Mumber 6552-63-2 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 6,5,5 and 2 respectively; the second part has 2 digits, 6 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 6552-63:
(6*6)+(5*5)+(4*5)+(3*2)+(2*6)+(1*3)=102
102 % 10 = 2
So 6552-63-2 is a valid CAS Registry Number.
InChI:InChI=1/C16H13ClO2/c1-19-15-9-2-12(3-10-15)4-11-16(18)13-5-7-14(17)8-6-13/h2-11H,1H3/b11-4+

6552-63-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name 1-(4-CHLOROPHENYL)-3-(4-METHOXYPHENYL)PROP-2-EN-1-ONE

1.2 Other means of identification

Product number -
Other names 4'-Chlor-4-methoxy-chalkon

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:6552-63-2 SDS

6552-63-2Relevant articles and documents

Synthesis, crystal growth, studies on vibrational spectroscopy and nonlinear optical properties of 4-methoxy-4′-chlorochalcone

Prabu,Nagalakshmi,Balaji,Srinivasan

, p. 446 - 453 (2014)

Good quality organic non linear optical (NLO) crystals of 4-methoxy-4′-chlorochalcone (4MCC) have been grown by slow evaporation solution growth method. The grown crystals were investigated with various spectroscopy techniques such as the structural confi

Synthesis of chalcone derivatives by phthalhydrazide-functionalized tio2-coated nano-fe3o4 as a new heterogeneous catalyst

Farahi, Mahnaz,Karami, Bahador,Keshavarz, Raziyeh,Nia, Forough Motamedi

, p. 407 - 414 (2021/09/07)

Phthalhydrazide immobilized on TiO2-coated nano Fe3O4 (Fe3O4-P) was synthesized and characterized by FT-IR, XRD, SEM, EDS and VSM analysis. The resulting magnetic nanocatalyst was used as a catalyst for the synthesis of chalcone derivatives which affords the desired products in good to excellent yields. This catalyst can be isolated readily after completion of the reaction by an external magnetite field and reused several times without significant loss of activity.

New nicotinic acid-based 3,5-diphenylpyrazoles: design, synthesis and antihyperlipidemic activity with potential NPC1L1 inhibitory activity

Shoman, Mai E.,Aboelez, Moustafa O.,Shaykhon, Montaser Sh. A.,Ahmed, Sanaa A.,Abuo-Rahma, Gamal El-Din A.,Elhady, Omar M.

, p. 673 - 686 (2020/02/25)

Nicotinic acid hydrazide was incorporated into new 4,5-dihydro-5-hydroxy-3,5-diphenylpyrazol-1-yl derivatives. Compounds 6a–h were synthesized, and their antihyperlipidemic activity was evaluated in high cholesterol diet-fed rat model. Compounds 6e, 6f were found to decrease the levels of serum total cholesterol by 14–19% compared to control group. Total triglycerides were also reduced by 24–28% and LDL cholesterol by 16%. As expected from parent niacin, compounds 6e and 6f caused an elevation of HDL cholesterol by 33–41%. Docking study supported the ability of designed compounds to block NPC1L1 active site in a manner similar to that observed with ezetimibe.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 6552-63-2